American Oncology Network (AONC) operates a community-based oncology network that partners with independent oncology and hematology practices. Recurring company news covers practice additions, clinic openings, physician recruitment, and regional expansion across community cancer-care markets.
Company updates also address support services for partner practices, including in-house pharmacy, laboratory support, clinical trial access, back-office operations, and revenue-diversifying programs. News involving the network’s practices includes outpatient oncology services, infusion therapy, blood-disorder care, CAR T-cell therapy, bispecifics, radiopharmaceuticals, patient advocacy, and participation in community oncology policy and industry forums.
Cencora (COR) signed a definitive agreement to acquire American Oncology Network (AONC), valuing the oncology network at $2.4 billion. The enterprise value comprises $2.3 billion at closing and contingent value rights—conditional payments—of up to $100 million. Cencora currently owns approximately 4% of AON. Assuming certain stockholders retain 25% through an equity rollover, Cencora expects to pay approximately $1.7 billion to reach 75% ownership.
The acquisition would expand Cencora’s oncology practice-support platform into twelve additional states. Cencora expects the acquisition to increase adjusted diluted earnings per share in the second year after closing. Required regulatory clearances and AON stockholder approvals remain pending. Separately, Cencora now expects fiscal 2026 adjusted diluted EPS of at least $17.90, versus its previous $17.75–$17.95 range, reflecting performance in U.S. Healthcare Solutions.
American Oncology Network (NASDAQ:AONC) announced the continued expansion of its radiology, imaging and radiopharmaceutical therapy (RPT) program, emphasizing growth in radioligand therapy centers and new physician leadership. Since launching its first radioligand therapy site in 2023 at Genesis Cancer & Blood Institute in Hot Springs, Arkansas, the network has grown to nine active radioligand therapy centers across Arizona, Florida, Arkansas, North Carolina, Texas and Ohio, with five additional sites under development.
According to the company, AON supports partner practices with patient population assessments, facility planning, regulatory guidance, physician training, staffing and ongoing operational oversight. AON added two key physician leaders: Robert J. McDonald, MD, FACNM, as radiology medical director and in-house reading radiologist, and Jason Berilgen, MD, as medical director of radiation oncology. They are tasked with overseeing radiology and radiation oncology services, protocol development, radiotheranostics and evidence-based treatment expansion across the network, reinforcing AON’s focus on bringing advanced cancer care into community settings.
American Oncology Network (NASDAQ:AONC) partner practice Bay Hematology Oncology in Maryland has added Board-certified medical oncologist and hematologist Bill Gai, MD, PhD, MS to its physician team.
According to American Oncology Network, Dr. Gai will see patients in Easton and Centreville and brings extensive academic, research and clinical experience.
American Oncology Network (NASDAQ:AONC) appointed Ella Friedman as president, network operations, effective June 11, 2026. She brings over 25 years of healthcare leadership across oncology, specialty care and multi-site operations and will oversee practice operations, strategic growth, integrations and infrastructure development across AON’s national community oncology network.
American Oncology Network (NASDAQ:AONC) and nonprofit CanCare announced a nationwide partnership on June 11, 2026 to deliver whole-person cancer care. The collaboration connects community oncology patients and caregivers with one-to-one emotional support from trained survivor and caregiver volunteers, complementing AON’s advanced clinical treatment.
The program, offered at no cost, supports patients at all stages of the cancer journey via phone, email, text, or in person. It builds on pilot programs at four AON partner practices, where positive feedback from patients and care teams highlighted the value of integrated peer support.
American Oncology Network (NASDAQ:AONC) announced a national partnership with Colla Health to expand oncology-focused behavioral health support across its community practices. The program launches at Hematology Oncology of Indiana and Genesis Cancer and Blood Institute and is expected to reach all AON partner practices nationwide by the end of 2026.
American Oncology Network (NASDAQ:AONC) and partner practice Florida Oncology and Hematology announced the addition of Board-certified medical oncologist and hematologist Dr. Vitor Pastorini to the physician team in Fort Myers and Cape Coral.
FOH now has nine medical oncologists and 15 advanced practice providers across five Florida locations.
American Oncology Network (NASDAQ:AONC) announced that multiple research studies co-authored by its physicians and leaders were selected for presentation at the ASCO 2026 Annual Meeting, held May 29–June 2 in Chicago.
Topics span clinical trials, AI-driven registries, pharmacovigilance, health disparities, and large language model evaluation, underscoring AON’s role in community oncology research.
AON reports that its practices currently offer access to more than 150 clinical trials, bringing innovative treatment options to local communities.
Zangmeister Cancer Center, a partner of American Oncology Network (NASDAQ:AONC), has become an affiliate of Ohio State’s OSUCCC – James through The James Cancer Network. The collaboration expands community-based cancer care across central Ohio, including access to more than 500 clinical trials and advanced therapies.
Patients gain local access to subspecialized oncology and hematology expertise, CAR T-cell therapy, stem cell transplant evaluation, tumor-infiltrating lymphocyte (TIL) therapy and proton therapy at OSUCCC – James, while maintaining strong ties to community care teams.
Elkhart Hematology and Oncology (formerly Elkhart Clinic’s hematology and oncology practice) joined American Oncology Network (AONC) on May 5, 2026, expanding patient access to clinical trials and community-based cancer care. The practice will continue onsite infusion, centralized lab/pathology, specialty pharmacy, care coordination and financial counseling.
Dr. Ahsanul Haque and Charisse Prall, FNP-BC will continue to lead clinical services and are accepting new patients.